Published on
Dec 5, 2025
Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight
The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to enter the crowded IgA nephropathy field. Daiichi Sankyo won reversal of an unfavorable ruling in its patent fight against Pfizer’s …
Source:
Fierce Pharma
-
Neutral
